ELGX Key Statistics, Chart & Performance
The current stock price of ELGX is 0.22 null. In the past month the price decreased by -77.55%. In the past year, price decreased by -96.71%.
ELGX Latest News, Press Relases and Analysis
About ELGX
Company Profile
Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis.
Company Info
Endologix Inc
2 MUSICK
IRVINE CA 92618
CEO: John Onopchenko
Phone: 949-595-7200
Endologix Inc / ELGX FAQ
Can you describe the business of Endologix Inc?
Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis.
Can you provide the latest stock price for Endologix Inc?
The current stock price of ELGX is 0.22 null. The price decreased by -23.88% in the last trading session.
Does Endologix Inc pay dividends?
ELGX does not pay a dividend.
How is the ChartMill rating for Endologix Inc?
ELGX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the ownership structure of Endologix Inc (ELGX)?
You can find the ownership structure of Endologix Inc (ELGX) on the Ownership tab.
ELGX Technical Analysis
ELGX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ELGX. ELGX has a bad profitability rating. Also its financial health evaluation is rather negative.
ELGX Financial Highlights
Over the last trailing twelve months ELGX reported a non-GAAP Earnings per Share(EPS) of -2.13. The EPS increased by 67.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -44.65% | ||
| ROA | -20.26% | ||
| ROE | N/A | ||
| Debt/Equity | 0.29 |